Search Drug Information, Interactions, Images, Dosage & Side Effects

Neuro features common in children with SARS-CoV-2–related inflammatory syndrome 11 May 2021

About 50 percent of children who develop Paediatric Inflammatory Multisystem Syndrome Temporally associated with SARS-CoV-2 (PIMS-TS) present with neurological features, according to a small study presented at AAN 2021.

Gait analysis differentiates progressive supranuclear palsy from Parkinson’s

11 May 2021

Swiss study: Rare spike in BP after COVID-19 vaccine

11 May 2021

Etanercept does better than methotrexate at keeping RA in remission

11 May 2021

Screening colonoscopy helps reduce CRC incidence, death

11 May 2021

Reintroduction of anatomy concepts improves surgical training among OBGYN residents

11 May 2021

Sirolimus reduces venous malformation size, eases GI bleeding in BRBNS

11 May 2021

SG’s Primary Care Network empowers private GPs to manage chronic diseases

11 May 2021

Weekly iron-folic acid supplementation combats iron, folate deficiency in young girls

11 May 2021

Foods with high acid load may promote pancreatic cancer

11 May 2021

Continuous anifrolumab exposure safe, produces sustained SLE disease activity improvement

11 May 2021

Product Highlight - Apidra SoloStar 07 Apr 2021;
Apidra SoloStar – Insulin glulisine 100 units/mL pre-filled pen

Product Highlight - Toujeo

07 Apr 2021

Product Highlight - Soliqua

07 Apr 2021

Management of MDROs in the ICU and the role of newer antimicrobial agents

Prof. David Paterson, 30 Mar 2021

Soliqua

Contents : Per 100 u/mL + 50 mcg/mL soln for inj (10-40 pen) Insulin glargine 3.64 mg (equiv to 100 u), lixisenatide 50 mcg. Per 100 u/mL + 33 mcg/mL soln for inj (30-60 pen) Insulin glargine 3.64 mg (equiv to 100 u), lixisenatide 33 mcg

Indications/Uses : In combination w/ metformin for adults w/ type 2 DM to improve glycaemic control when metformin alone, or metformin combined w/ another oral glucose lowering drugs, or w/ basal insulin does not provide adequate glycaemic control.